October is Intellectual Property (IP) Awareness Month, marking a crucial time to recognize the vital role that IP plays in driving innovation, strengthening the economy, and protecting creators’ rights.
Read MoreThe Congressional Budget Office (CBO) recently released a report examining the 340B Drug Pricing Program—a program originally designed to help low-income and vulnerable patients gain access to affordable medicines. The findings raise troubling questions about whether the program is delivering on its promise.
Read MoreRecently, drug manufacturer Pfizer and the Trump Administration announced a deal aimed at lowering prescription drug costs for Americans.
Read MorePresident Trump’s administration is rolling out a questionable new tariff policy: 100% tariffs on pharmaceuticals made outside the United States. The ostensible goal is to deliver more domestic manufacturing, but instead, it creates real risks for patients, affordability, and access to care.
Read MoreThe Trade Alliance to Promote Prosperity recently joined a coalition of 20+ organizations in signing onto a letter to President Trump and Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., opposing potential price control measures included in the administration’s Most Favored Nation plan.
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., has a column published in the DC Journal today, "AI Action Plan Sets the Right Course," which discusses President Trump's plan for the United States to remain the world's leader on artificial intelligence.
Read MoreThe Trade Alliance to Promote Prosperity signed onto a coalition letter urging Congress to pass common sense Pharmacy Benefit Manager (PBM) reforms…
Read MoreThe Trade Alliance to Promote Prosperity is applauding a decision by Bristol Myers Squibb, one of the largest American pharmaceutical innovators, to require the U.K.’s National Health Service to pay its fair share for a newly released schizophrenia treatment, Cobenfy…
Read MoreThe Trade Alliance to Promote Prosperity recently joined a coalition of three dozen organizations in signing a letter to U.S. Secretary of Commerce Howard Lutnick, urging the Trump administration to abandon the idea of imposing a patent tax…
Read MoreThe Trade Alliance to Promote Prosperity recently submitted comments to the Health Resources and Services Administration (HRSA), supporting a proposed 340B rebate pilot program…
Read MoreThe Trade Alliance to Promote Prosperity applauds a new healthcare initiative called “Most Favored Patient” recently launched by the organization Unleash Prosperity Now, which aims to put American patients first and lower healthcare costs…
Read MoreThe Trade Alliance to Promote Prosperity recently joined 10 coalition partners in signing a letter urging President Trump to reject Korea’s discriminatory digital trade practices…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., contributed comments for a video from a coalition of conservative and free market organizations, urging Congress to oppose Most Favored Nation drug pricing schemes…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., penned an op-ed for the DC Journal/Inside Sources today, “On Drugs, Is Trump Tired of Winning or What?” In the op-ed, TAPP explains why President Trump’s Most-Favored-Nation drug pricing scheme would be bad for American pharmaceutical innovation and for patients…
Read MoreOn Thursday, July 24, the Justice Department’s Antitrust Division and the Federal Trade Commission, along with the Department of Commerce and the Department of Health and Human Services, hosted their second of three listening sessions as part of implementing President Trump’s Executive Order No. 14273, Lowering Drug Prices by Once Again Putting Americans First…
Read MoreThe Trade Alliance to Promote Prosperity is applauding the efforts of 18 Republican Senators who sent a letter to U.S. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer endorsing efforts “to ensure foreign nations pay their fair share toward the cost of pharmaceutical research and development.”…
Read MoreCongresswoman Doris Matsui (D-CA) and Senator Peter Welch (D-VT) recently re-introduced a highly problematic bill called the 340B PATIENTS Act. The Trade Alliance to Promote Prosperity is encouraging Congress to reject the bill…
Read MoreThe Trade Alliance to Promote Prosperity recently signed onto a letter with 40+ coalition partners asking Congress to crack down on the 340B drug-pricing program, which provides discounted prices for certain so-called safety-net providers to purchase outpatient drugs…
Read MoreThe Trade Alliance to Promote Prosperity recently responded to the U.S. Trade Representative’s “Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation,” which the USTR issued pursuant Executive Order 14297, titled Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients. TAPP took the opportunity to highlight the detrimental effects of implementing an MFN scheme…
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., has an op-ed, "Trump Policy Threatens Biomedical Innovation," appearing in the DC Journal/Inside Sources today…
Read More